Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

179.12 -5.44 (-2.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' ↗

November 20, 2025

Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation.

Via Benzinga

Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position ↗

November 20, 2025

Via Stocktwits

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? ↗

October 16, 2025

Via Stocktwits

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

What to Expect from Praxis Precision Medicine's Earnings ↗

August 01, 2025

Via Benzinga

Meet the Biotech Stock That Just Jumped 251% Higher ↗

October 26, 2025

Find out what sent this typically overlooked stock through the roof.

Via The Motley Fool

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗

October 17, 2025

Via Benzinga

Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗

October 17, 2025

Via Benzinga

Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win ↗

October 17, 2025

Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data.

Via Stocktwits

Topics Death

Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts ↗

March 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 16, 2025

Via Benzinga

Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗

October 16, 2025

Via Benzinga

Topics Stocks

The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% ↗

October 16, 2025

The company is working on a treatment for essential tremor. Positive results shocked investors following a negative readout in February.

Via Investor's Business Daily

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗

October 16, 2025

Via Benzinga

Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings ↗

October 16, 2025

Via Benzinga

Topics Stocks

Stay updated with the stocks that are on the move in today's pre-market session. ↗

October 16, 2025

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 16, 2025

Via Benzinga

Praxis Precision Medicines Stock Doubles - Here's Why ↗

October 16, 2025

Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints.

Via Benzinga

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures ↗

August 04, 2025

Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.

Via Benzinga

Praxis (PRAX) Q2 Loss Widens 90% ↗

August 04, 2025

Via The Motley Fool

Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine ↗

August 04, 2025

Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 01, 2025

Via Benzinga

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside ↗

May 07, 2025

Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.

Via Benzinga

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 07, 2025

Via Benzinga

Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts ↗

May 01, 2025

Via Benzinga

Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) ↗

April 08, 2025

Via Benzinga

Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate ↗

March 03, 2025

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.